netFormulary Sheffield Teaching Hospitals NHS
NHS Foundation Trust  
 Search
 Formulary Chapter 17: Other NICE TA-approved drugs - Full Chapter
Notes:
Drugs which have received a positive technology appraisal from NICE but have not been formally approved by the Trust's Medicine Management and Therapeutics Committee or its subgroups. These drugs will be made available in accordance with local policy or other relevant guidance.
 Details...
17  Expand sub section  NICE TA drugs
Abemaciclib (Verzenios® )
View adult BNF View SPC online
Restricted Drug Restricted
Red

tablets

 
Link  NICE guidance - With An Aromatase Inhibitor For Previously Untreated, Hormone Receptor-Positive, HER2-Negative, Locally Advanced Or Metastatic Breast Cancer
Link  NICE guidance - With Fulvestrant For Treating Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer After Endocrine Therapy
   
Cytotoxic Drug Arsenic trioxide (TRISENOX ® )
View adult BNF View SPC online
Formulary
Red

concentrate for solution for infusion

 
Link  NICE guidance
   
Avelumab (Bavencio®)
View adult BNF View SPC online
Formulary
Red

concentrate for solution for infusion

 
Link  NICE guidance
   
Axicabtagene ciloleucel (YESCARTA)
View adult BNF View SPC online
Formulary

cell dispersion for infusion

 
Link  NICE guidance
   
Binimetinib (Mektovi®)
View adult BNF View SPC online
Restricted Drug Restricted
Red

tablets

 
Link  NICE guidance
   
Cemiplimab (LIBTAYO® )
View adult BNF View SPC online
Formulary

Concentrate for solution for infusion

 
Link  NICE guidance
   
Dacomitinib (Vizimpro®)
View adult BNF View SPC online
Formulary
Red

tablets

 
Link  NICE guidance
   
Dinutuximab beta (Qarziba® )
View adult BNF View SPC online
Formulary
Red

concentrate for solution for infusion

 
Link  NICE guidance
   
Ertugliflozin (Steglatro®)
View adult BNF View SPC online
Formulary

tablets

 
Link  NICE guidance - As Monotherapy Or With Metformin For Treating Type 2 Diabetes
Link  NICE guidance - With Metformin And A Dipeptidyl Peptidase-4 Inhibitor For Treating Type 2 Diabetes
   
Holoclar
View adult BNF View SPC online
Formulary Ex vivo expanded autologous human corneal epithelial cells containing stem cells.

Treatment not provided at STH 
Link  NICE guidance
   
Ibandronic acid (Bonviva®)
View adult BNF View SPC online
Formulary tablets 
Link  NICE guidance
   
Interferon beta (Extavia®)
View adult BNF View SPC online
Formulary

injection

 
Link  NICE guidance
   
Letermovir (PREVYMIS®)
View adult BNF View SPC online
Formulary

tablets

 
Link  NICE guidance
   
Mannitol (Bronchitol® )
View adult BNF View SPC online
Formulary
High Cost Medicine
Inhalation powder-capsules 
Link  NICE guidance
   
Cytotoxic Drug Midostaurin (Rydapt®)
View adult BNF View SPC online
Formulary
Red

capsules

 
Link  NICE guidance
   
Naftidrofuryl
View adult BNF View SPC online
Formulary capsules 
Link  NICE guidance
   
Nalmefene (Selincro®)
View adult BNF View SPC online
Formulary
Red
tablets 
Link  NICE guidance
   
Naltrexone
View adult BNF View SPC online
Formulary
Amber
tablets

AMBER if advice available from specialist services, and prescribed in accordance with national treatment guidelines – otherwise RED. 
Link  NICE guidance
   
Nusinersen (Spinraza ®)
View adult BNF View SPC online
Formulary

intrathecal injection

 
Link  NICE guidance
   
Risankizumab (Skyrizi®)
View adult BNF View SPC online
Formulary

injection

 
Link  NICE guidance
   
Talimogene laherparepvec (Imlygic®)
View adult BNF View SPC online
Restricted Drug Restricted

injection

 

Not used at STH

 
Link  NICE guidance
   
Vortioxetine (Brintellix®)
View adult BNF View SPC online
Restricted Drug Restricted tablets 
Link  NICE guidance
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Definition Certain drugs that are initiated by a specialist but are suitable for GPs to continue ongoing prescribing. The specialist should provide the GP with necessary information and support in order for treatment to be managed safely in primary care. Shared care protocols (SCP) or prescribing guidelines may be available. 1. Requiring specialist assessment to enable patient selection. 2. Requiring a period of monitoring by a specialist. 3. The initial prescription should normally be issued by the specialist unless the agreed SCP states otherwise.  

Black

Definition A drug which should not be initiated in Sheffield unless exceptional circumstances apply to the individual concerned and an Individual Funding Request (IFR) has been agreed by NHS Sheffield. The drug should not be withdrawn from patients already established on treatment but other treatment options should be considered at routine review. Criteria 1. There is a clear Yorkshire and Humber Specialised Commissioning Group decision to not routinely fund usage of the drug. 2. There is a NICE recommendation that the drug should not be prescribed on the NHS for the condition specified. 3. A drug requiring specific commissioning arrangements to be clarified and put in place before prescribing can take place.  

Green

Drugs for which GPs should take full responsibility for initiating and ongoing prescribing.   

Red

Definition Prescribing and ongoing supply is normally undertaken by a consultant or other physician within a secondary care service. In some exceptional circumstances and following discussion between primary and secondary care, GPs may consider it to be in the patient’s best interest for drugs in the Red section of the traffic light scheme to be prescribed in primary care. Red traffic light drugs meet one or more of the following criteria: 1. Require specialist assessment to enable patient selection, initiation, ongoing treatment and monitoring of efficacy, toxicity or adverse effects. 2. Specifically designated as “hospital only “either by product licence or by DH 3. Hospital initiated clinical trial materials used in accordance with the trial protocol 4. Not listed in the current BNF or BNF (C). 5. Being used to treat a condition that is not suitable for primary care prescribing because of disease specific requirements, complexity or defined commissioning arrangements.  

netFormulary